

**APPROVED**

**By Jean Gildner at 10:39 am, Jun 07, 2016**

**From:** [Margarita Aguilera](#)  
**To:** [Yao, Michael \(CBER\)](#)  
**Cc:** [Schneider, Bruce](#); [Gildner, Jean](#); [Riggins, Patrick](#); [David Recker](#)  
**Subject:** RE: Request for additional clinical information  
**Date:** Monday, May 23, 2016 7:16:16 PM

---

Dear Dr. Yao,

In response to your request for additional clinical information dated 20 May 2016, please find our responses below:

1. Regarding clinical evaluation in SUMMIT study, do you have clinical data (KOOS pain and function) before visit 6 (week 24)? If so, please provide a summary for FDA review.

Per protocol the MACI00206 study did not collect KOOS scores prior to week 24. The rationale behind the 24 week time point was to provide subjects with adequate time to recover from the arthroscopy (microfracture) or the arthrotomy (MACI) procedures, acknowledging that the MACI-treated subjects underwent a more invasive procedure. MACI00206 CSR Section 9.5.2.1. Knee Injury and Osteoarthritis Outcome Score, provides a description of the collection time points for the KOOS efficacy assessments.

2. Please provide subgroup analysis by number of lesions and by subject age, using some reasonable cut-off determine "younger" vs "older."

Section 4 of the Integrated Summary of Efficacy (ISE) included in Module 3.5.5.3, shows a comparison of KOOS pain and function results across subpopulations at year 2. ISE, Table 6 (page 196) shows the results for subjects with 1 or >1 cartilage lesion. ISE, Table 11 (pages 207 and 208) shows the results for subjects based on age. The by age subgroup analysis split the subjects into 2 groups based on the median age of MACI-treated subjects in the MACI00206 study ( $\leq 35$  and  $> 35$ ). In all subgroups, MACI KOOS pain and function scores were superior to microfracture.

We trust this addresses your questions.

Regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street  
[Cambridge, MA 02139](#)  
[maguilera@vcel.com](mailto:maguilera@vcel.com);  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS

ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Margarita Aguilera  
**Sent:** Sunday, May 22, 2016 10:04 PM  
**To:** 'Yao, Michael (CBER)'  
**Cc:** Schneider, Bruce; Gildner, Jean  
**Subject:** RE: Request for additional clinical information

Dear Dr. Yao,

This is to acknowledge receipt of your request for information. I will get back to you with additional information on Monday.

Regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street  
Cambridge, MA 02139  
[maguilera@vcel.com](mailto:maguilera@vcel.com)  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Yao, Michael (CBER) [<mailto:Michael.Yao@fda.hhs.gov>]  
**Sent:** Friday, May 20, 2016 9:02 PM  
**To:** Margarita Aguilera  
**Cc:** Schneider, Bruce; Gildner, Jean  
**Subject:** Request for additional clinical information  
**Importance:** High

Hi Aguilera,

Please provide following information for us:

1. Regarding clinical evaluation in SUMMIT study, do you have clinical data (KOOS pain and function) before visit 6 (week 24)? If so, please provide a summary for FDA review.
2. Please provide subgroup analysis by number of lesions and by subject age, using some reasonable cut-off determine "younger" vs "older."

Thanks.

Michael